Main Session
Sep 28
SS 15 - Immunotherapy Integration and Immuno Biomarkers Across Mucosal and Cutaneous SCC

171 - A Phase II, Multicenter, Single-Arm Clinical Trial of Response-Adapted Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART

10:45am - 10:55am ET
Screen: 7

Presenter(s)

Christopher Barker, MD - Memorial Sloan Kettering Cancer Center, New York, NY